This study aims to test a medicine called Deucravacitinib in teenagers with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition causing red, scaly patches. The study will check how well the medicine works, if it’s safe, and how the body processes it.

Eligibility: Participants must have had plaque psoriasis for at least 6 months. They need a Psoriasis Area and Severity Index (PASI) of 12 or more, meaning they have a moderate to severe condition. Female participants must not be pregnant or breastfeeding and should use effective birth control if they can have children. Important Exclusion Criteria: Participants should not weigh less than 30 kilograms and must not have other types of psoriasis or skin conditions that could affect the study results. They should not have serious infections, certain viruses, or have had live vaccines recently.

• The study involves multiple visits to the research site.
• Participants will be monitored for safety and treatment efficacy.
• Participants must not have used Deucravacitinib before.